Glofitamab and R-CHOP Combination for High-Risk DLBCL
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for high-risk diffuse large B-Cell Lymphoma (DLBCL) defined by circulating tumor DNA (ctDNA) are inadequate, with limited accuracy in identifying high-risk patients and suboptimal response rates to standard therapies like R-CHOP.
Innovation Solution
Administering the bispecific antibody glofitamab, which targets CD3 and CD20, in combination with chemotherapy, specifically R-CHOP, to patients identified as high-risk based on less than 2.5-log reduction in ctDNA levels after one or two cycles of chemotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard R-CHOP chemotherapy is used to treat DLBCL patients, then treatment coverage is broad, but response rates are suboptimal in high-risk patients (less than 60% cure rate)
Solution Approach 1:
The treatment approach is customized based on local ctDNA characteristics in each patient. Patients are stratified into high-risk and standard-risk groups based on their individual ctDNA reduction response, and the high-risk group receives the adapted combination therapy of glofitamab plus R-CHOP, while standard-risk patients receive conventional R-CHOP alone.
Solution Approach 2:
The treatment protocol dynamically adjusts based on intermediate ctDNA measurements. After one or two cycles of R-CHOP, patients are re-evaluated using ctDNA reduction criteria, and the treatment plan is modified accordingly - high-risk patients are escalated to combination therapy while standard-risk patients continue with conventional treatment.
2Measurement precision
If IPI scoring system is used to identify high-risk patients, then risk stratification is established, but accuracy is insufficient (cannot identify all high-risk patients)
Solution Approach 1:
The system uses ctDNA measurements as feedback to continuously monitor and reassess patient risk status. Intermediate ctDNA levels after one or two treatment cycles provide real-time feedback on treatment response, allowing dynamic reclassification of patients from standard-risk to high-risk if inadequate reduction is observed, thereby improving identification accuracy beyond static IPI scoring.
Solution Approach 2:
The patent introduces a new measurement parameter (ctDNA reduction level) to replace or supplement the traditional IPI scoring parameters. By measuring the quantitative change in ctDNA levels rather than relying on baseline clinical characteristics, the system achieves more precise and reliable risk stratification.
3Loss of time
If treatment response is assessed only after treatment completion, then overall treatment outcome is evaluated, but salvageable potential is lost in non-responders
Solution Approach 1:
The assessment of treatment response is performed preliminarily after just one or two cycles of chemotherapy rather than waiting for completion of the full treatment course. This early interim assessment using ctDNA measurements allows identification of non-responders before significant time is lost, enabling timely intervention with escalated therapy for high-risk patients.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves high overall response rates (at least 95%) and complete response rates (at least 85%) in patients with high-risk DLBCL, significantly improving treatment outcomes for this patient subgroup.
Implementation Method 1
Glofitamab, a CD20×CD3 bispecific antibody, engages and redirects T cells to eliminate B cells
Data Source
AI summary
The present invention relates to methods of treating previously untreated diffuse Large B-Cell Lymphoma (DLBCL) defined as high risk by Circulating Tumor DNA (ctDNA), by administering glofitamab and in combination with chemotherapy.